Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The airway goblet cell.

Duncan F Rogers1

  • 1Thoracic Medicine, National Heart and Lung Institute (Imperial College), Dovehouse Street, London, SW3 6LY, UK. duncan.rogers@ic.ac.uk

The International Journal of Biochemistry & Cell Biology
|December 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases.

Pharmacology·2015
Same author

Therapeutic options for hydrating airway mucus in cystic fibrosis.

Pharmacology·2015
Same author

Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells.

Respiratory research·2012
Same author

New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.

Journal of aerosol medicine and pulmonary drug delivery·2010
Same author

Phytoceuticals: the new 'physic garden' for asthma and chronic obstructive pulmonary disease.

Expert review of respiratory medicine·2010
Same author

Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy.

Current opinion in allergy and clinical immunology·2009

Airway goblet cells secrete mucin and increase in number during chronic lung insult. Targeting signaling pathways like epidermal growth factor (EGF) offers new therapies for mucus hypersecretion in asthma and COPD.

Area of Science:

  • Pulmonary Medicine
  • Cell Biology
  • Respiratory Physiology

Background:

  • Airway goblet cells are crucial for mucin secretion and hyperplasia in response to chronic inhaled irritants.
  • Mucin hypersecretion and goblet cell hyperplasia are pathological hallmarks of diseases like asthma and COPD.
  • Key molecular players include Myristoylated alanine-rich C kinase (MARCKS), protein kinases (PKC, PKG), epidermal growth factor (EGF), and calcium-activated chloride channels (CLCA).

Purpose of the Study:

  • To elucidate the molecular mechanisms regulating goblet cell function, specifically mucin secretion and hyperplasia.
  • To identify key signaling pathways and molecules involved in airway goblet cell pathophysiology.
  • To explore novel therapeutic targets for reversing or preventing goblet cell hyperplasia and mucus hypersecretion.

Related Experiment Videos

Main Methods:

  • Review of molecular signaling pathways governing goblet cell function.
  • Analysis of the roles of MARCKS, PKC, PKG, EGF cascade, CLCA, and Bcl-2 in goblet cell hyperplasia.
  • Identification of potential therapeutic strategies based on molecular targets.

Main Results:

  • MARCKS regulates mucin exocytosis, with PKC and PKG involvement.
  • EGF cascade and CLCA are implicated in goblet cell hyperplasia development.
  • Bcl-2 contributes to the maintenance of goblet cell hyperplasia.
  • Goblet cell hyperplasia and mucus hypersecretion are key features of asthma and COPD.

Conclusions:

  • Understanding the molecular basis of goblet cell hyperplasia is critical for treating airway hypersecretory diseases.
  • Inhibitors of EGF receptor tyrosine kinase and CLCA represent promising therapeutic avenues.
  • Pharmaceuticals targeting these pathways are available for clinical trials in conditions like asthma and COPD.